Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
ALPP/ALPPL2 mAb - 01 | PCC | Solid Tumor | Endometrial cancer,Ovarian cancer | ||
BCMA VHH - 01 | Lead | Hematological Malignancy | Multiple myeloma | ||
CCR8 mAb - 01 | PCC | Solid Tumor | Solid tumor | ||
CCR8 mAb - 02 | Lead | Solid Tumor | Solid tumor | ||
CCR8 mAb - 03 | PCC | Solid Tumor | Solid tumor | ||
CD25 mAb - 01 | PCC | Solid Tumor | Solid tumor | ||
CDH17 mAb - 03 | PCC | Solid Tumor | Colorectal cancer,Gastric Cancer | ||
CXCR4 mAb - 01 | Lead | Hematological Malignancy,AutoImmunity | Blood tumor,Solid tumor |
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
5-HT1F agonist | Small molecule | Neurological disease | Migraine | Phase I | Global |
EGFR inhibitor | Small molecule | Oncology/Cancer | Esophageal Carcinoma Pancreatic Cancer | Phase III | Global |
FLT3 Inhibition | Small molecule | Oncology/Cancer | AML | Phase III | Global |
TNFα and TGF-β1 inhibitor | Small molecule | Respiratory disease | IPF | Phase II | Global (except China) |
Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase III | Global (except China) |
PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Hematologic malignancies | Phase I | Global |
Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase I | Global (except China) |
RET high selective inhibitor | Small molecule | Oncology/Cancer | NSCLC,Medullary thyroid cancer,Thyroid cancer | Phase I | Global |
A SSRI & Partial 5-HT1A Agonist | Small molecule | Neurological disease | Depression | Phase III | Global |
sGC stimulator | Small molecule | Cardiovascular | PAH,CTEPH,HFrEF,CKD | Phase I | Global |
XO/URAT1 Dual inhibitor | Small molecule | Metabolic disease | Hyperuricimia | Phase I | Global |
FXR Agonist | Small molecule | Metabolic disease | NASH | Phase II | Global |
SGLT2 inhibitor | Small molecule | Metabolic disease | Diabetes | Phase III | Global (except China) |
FXR Agonist | Small molecule | Metabolic disease | Diabetic kidney disease | Phase I | Global |
ACC inhibitor treating NASH | Small molecule | Metabolic disease | NASH | IND | Global |
Oxazolidone (new compounds) antibiotics | Small molecule | Infectious and parasitic diseases | gram-positive bacterial infections | IND | Global |
HIF-PHs inhibitor for CKD and Renal anemia | Small molecule | Blood and Clotting disease | CKD,Renal anemia | Phase I | Global (except China) |
PI3K/mTOR dual inhibitor | Small molecule | Oncology/Cancer,Respiratory disease | IPF,solid tumor | Phase I | Global (except China) |
B7H3+CD3 BsAb | Monospecific antibody | Oncology/Cancer | Solid Tumor | IND | Global |
Viscous Gel Temozolomide | Small molecule | Oncology/Cancer,Neurological disease | Glioblastoma | Phase I | Global except CIA |
Modified vilazodone | Small molecule | Neurological disease | Major Depressive Disorder | BE | Global |
CLDN 18.2 CAR-T | Cell therapy | Oncology/Cancer | Gastric Cancer,Pancreatic Cancer | IND | Global |
EpCAM CAR-T | Cell therapy | Oncology/Cancer | Colorectal Cancer,Gastric Cancer,Other Cancer | IIT | Global |
GLP-1/GIP/GCG fusion protein | Fusion/Recombination protein | Metabolic disease | T2DM,Obesity | IND | Global |
PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Advanced solid tumors | Phase I | Global |
PARP inhibitor | Small molecule | Oncology/Cancer | Advanced malignant solid tumors | Phase I | Global |
GLP-1/GIP/FGF21 fusion protein | Fusion/Recombination protein | Metabolic disease | NASH,Type 2 diabetes,hyperlipidemia | Preclinical | Global (except China) |
Liver-Targeting THR-β Agonist | Small molecule | Metabolic disease | Nonalcoholic Steatohepatitis (NASH) | Phase I | Global |
PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Solid tumor,Hematological malignancies | PCC | Global |
Best-in-class IRAK4 Degrader | Immunological disease | Psoriasis/RA/Inflammatory bowel disease (IBD)/autoimmune inflammatory diseases | PCC | Global |
2% serum diluted by Dilution Buffer : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 2.383 and 2.148; 2% serum diluted by DB-02 : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 0.262 and 0.263. In the existence of DB-02, the serum background values significantly decreased. Note: Dilution Buffer is Wash Buffer with 0.5% (w/v) bovine serum albumin (BSA), 50 mL.
This web search service is supported by Google Inc.